Dr. Amit Oza, MD
Claim this profilePrincess Margaret Cancer Centre
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
30 reported clinical trials
50 drugs studied
About Amit Oza, MD
Education:
- Obtained an MD (Medical Degree) from St. Bartholomew's Hospital, University of London, UK.
- Holds an MBBS (Bachelor of Medicine, Bachelor of Surgery), a standard medical degree in the UK.
Experience:
- Currently serves as the Head of the Department of Medical Oncology & Hematology at Princess Margaret Cancer Centre.
- Acts as the Medical Director of the Cancer Clinical Research Unit and Co-Director of The Bras Drug Development Program at the same institution.
- Holds a position as a Senior Scientist at The Ontario Cancer Institute and a Professor of Medicine at the University of Toronto.
- Has been a principal or co-investigator in over 100 clinical trials focusing on gynecological cancer and advanced colorectal malignancies.
Area of expertise
1Ovarian Cancer
Global LeaderStage IV
Stage III
FRα positive
2Fallopian Tube Cancer
FRα positive
Stage IV
BRCA positive
Affiliated Hospitals
Clinical Trials Amit Oza, MD is currently running
Mirvetuximab + Bevacizumab
for Ovarian Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting2 awards Phase 3
OC-001
for Advanced Cancers
This trial is testing a new treatment called OC-001, both by itself and with other drugs that help the immune system fight cancer. It aims to help patients with various types of cancer by making their immune system better at attacking cancer cells.
Recruiting1 award Phase 1 & 214 criteria
More about Amit Oza, MD
Clinical Trial Related5 years of experience running clinical trials · Led 30 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Amit Oza, MD has experience with
- Niraparib
- Paclitaxel
- Carboplatin
- Olaparib
- Mirvetuximab Soravtansine
- Pembrolizumab
Breakdown of trials Amit Oza, MD has run
Ovarian Cancer
Fallopian Tube Cancer
Cancer
Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Amit Oza, MD specialize in?
Amit Oza, MD focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are Stage III.
Is Amit Oza, MD currently recruiting for clinical trials?
Yes, Amit Oza, MD is currently recruiting for 10 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Amit Oza, MD has studied deeply?
Yes, Amit Oza, MD has studied treatments such as Niraparib, Paclitaxel, Carboplatin.
What is the best way to schedule an appointment with Amit Oza, MD?
Apply for one of the trials that Amit Oza, MD is conducting.
What is the office address of Amit Oza, MD?
The office of Amit Oza, MD is located at: Princess Margaret Cancer Centre, Toronto, Ontario M5G 2M9 Canada. This is the address for their practice at the Princess Margaret Cancer Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.